| Identification | Back Directory | [Name]
[2H8]-Bendamustine Hydrochloride | [CAS]
1185068-23-8 | [Synonyms]
Bendamustine-d8 HCl
Bendamustine hydrochloride salt
[2H8]-Bendamustine Hydrochloride
[2H8]-Bendamustine hydrochloride salt | [Molecular Formula]
C16H22Cl3N3O2 | [MOL File]
1185068-23-8.mol | [Molecular Weight]
394.72 |
| Hazard Information | Back Directory | [Uses]
Bendamustine-d8 (hydrochloride) is deuterium labeled Bendamustine (hydrochloride). Bendamustine hydrochloride (SDX-105), a purine analogue, is a DNA cross-linking agent. Bendamustine hydrochloride activats DNA-damage stress response and apoptosis. Bendamustine hydrochloride has potent alkylating, anticancer and antimetabolite properties[1]. | [References]
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Leoni LM, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14(1):309-17. DOI:10.1158/1078-0432.CCR-07-1061
[3] Cives M, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013 May;25(5):1108-17. DOI:10.1016/j.cellsig.2013.01.020
[4] Ackler S, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol. 2012 Oct;167(4):881-91. DOI:10.1111/j.1476-5381.2012.02048.x |
|
| Company Name: |
Pharma Affiliates
|
| Tel: |
172-5066494 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList694812/0_EN.htm |
|